Drug intelligence / Profile preview

INT001

Development stage: Unknown
Administration: Intratumoral

Overview

INT001 is an investigational drug being evaluated for its ability to ablate liver tumors, including hepatocellular carcinoma and metastatic liver tumors, in an outpatient setting. Administered via needle-based percutaneous injection directly into the tumor, its primary goal is to entirely kill the tumor cells. The ongoing clinical trial (NCT06689670) is assessing both its efficacy in tumor ablation and its safety profile in adult participants.

Targets

SLC1A5 (Alanine/serine/cysteine transporter 2)

Beyond the preview

Go deeper on INT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT001.

Explore the full profile